Sort   by:  
 Page size 
ProteomicsRed blood cell BCL-xL is required for Plasmodium falciparum survival: insights into host-directed malaria therapies
The development of antimalarial drug resistance is an ongoing problem threatening progress towards malaria elimination, and antimalarial treatments are urgently needed for drug-resistant malaria infections. Host-directed therapies (HDT) represent an attractive strategy for the devel-opment of new an...
ORGANISM(S): Homo sapiens (Human) Plasmodium falciparum 365.1 
2022-05-19 | PXD032276 | Pride
Bcl-xl  malaria  plasmodium falciparum  host-directed therapy  red blood cells  host-parasite in-teraction 
ProteomicsPhosphorylation of Bcl-xL by ERK1
The anti-apoptotic function of Bcl-xL in the heart against reperfusion injury is diminished by K-Ras-Mst1-mediated phosphorylation of Ser14, which allows dissociation of Bcl-xL from Bax and promotes cardiomyocyte death. Here we show that Ser14 phosphorylation of Bcl-xL is also promoted by hemodynami...
ORGANISM(S): Homo sapiens (Human) 
2023-09-06 | PXD045118 | Pride
Human Phosphorylation Mitogen-activated protein kinase 3 Bcl-2-like protein 1 
ProteomicsAllosteric regulation of BH3-in-groove interactions by tail anchors of BCL-xL complexes limits BH3 mimetic antagonism
BCL-xL promotes cell survival by binding BH3-only initiators through its hydrophobic groove. Combining resonance energy transfer assays and molecular dynamics simulations, we unravel that membrane anchoring of BCL-xL via its C-terminal tail selectively advantages binding to membrane-anchored PUMA in...
ORGANISM(S): Homo sapiens (Human) 
2025-12-08 | PXD066303 | Pride
Puma Tail anchors Bcl-xl Bax Tripletof 5600+ Bh3 mimetic Swath 
TranscriptomicsMicroRNA expression data from Bcl-xL silenced A549 lung adenocarcinoma cells
Bcl-xL is an anti-apoptotic protein that is frequently found to be overexpressed in non-small cell lung cancer leading to an inhibition of apoptosis and poor prognosis. Recently, the role of miRNAs in regulating apoptosis and cell survival during tumorigenesis has become evident, with cancer cells s...
ORGANISM(S): Homo sapiens 
2013-05-18 | E-GEOD-47059 | biostudies-arrayexpress
ProteomicsDevelopment and crystal structures of a more potent second-generation dual degrader of BCL-2 and BCL-xL
Overexpression of BCL-xL and BCL-2 play key roles in tumorigenesis and cancer drug resistance. Advances in PROTAC technology facilitated recent development of the first BCL-xL/BCL-2 dual degrader, 753b, a VHL-based degrader with improved potency and reduced toxicity compared to previous small molec...
ORGANISM(S): Homo sapiens (Human) 
2024-03-12 | PXD049976 | Pride
Protac Crystal structure Ubiquitin Ternary complex Degrader E3 ligase Bcl-xl/bcl-2 
ProteomicsIdentification of ubiquitination site in BCL-XL after PROTAC DT2216 treatment
The availability of a suitable lysine for PROTAC-mediated ubiquitination can also determine the degradative ability of a protein target and the selectivity of a PROTAC. PROTAC DT2216 selectively triggers ubiquitination and degradation of BCL-XL. In this study, we identify K87 is the key ubiquitinate...
ORGANISM(S): Homo sapiens (Human) 
2019-10-08 | PXD015454 | Pride
Bcl-xl Ubiquitination site K87 Protac Dt2216 
GenomicsThe effect of Bcl-xL overexpression on H3K3me3
The effect of Bcl-xL overexpression on H3K3me3
PRJNA915095 | ENA
ProteomicsDT2216 is a specific BCL-XL PROTAC
To validate the specificity of DT2216, we used the stable isotope labeling with amino acids in cell culture (SILAC) and liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomics to analyze the changes in proteins in WI-38 normal human diploid fibroblasts after DT2216 and DT2216NC tr...
ORGANISM(S): Homo sapiens (Human) 
2019-10-08 | PXD010878 | Pride
Dt2216 bcl-xl protac silac lc-ms/ms 
ProteomicsDevelopment and crystal structures of a more potent second-generation dual degrader of BCL-2 and BCL-xL
Overexpression of BCL-xL and BCL-2 play key roles in tumorigenesis and cancer drug resistance. Advances in PROTAC technology facilitated recent development of the first BCL-xL/BCL-2 dual degrader, 753b, a VHL-based degrader with improved potency and reduced toxicity compared to previous small molec...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2024-02-21 | MSV000094144 | MassIVE
GenomicsBCL-XL inhibition induces an FGFR4 mediated rescue response in colorectal cancer
BCL-XL inhibition induces an FGFR4 mediated rescue response in colorectal cancer
PRJNA669160 | ENA
Sort   by:  
 Page size